Los Angeles Capital Management
LENZ

Los Angeles Capital Management’s LENZ Therapeutics LENZ Stock Holding History

Los Angeles Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$303K Buy
33,071
+29,183
+751% +$410K ﹤0.01% 1022
2025
Q4 		$118K Buy
+3,888
New +$113K ﹤0.01% 1379

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Los Angeles Capital Management's LENZ Position: Q1 2026 in Review

Los Angeles Capital Management increased its LENZ Therapeutics (LENZ) stake by 751% in Q1 2026, buying an estimated $410K and bringing the position to 33,071 shares worth $303K. The position accounts for ﹤0.01% of the portfolio, ranked #1022.

Los Angeles Capital Management first reported a position in LENZ in Q4 2025 and has held it in 2 quarters since. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Los Angeles Capital Management held 33,071 shares of LENZ Therapeutics worth $303K as of Q1 2026.
  • Los Angeles Capital Management bought 29,183 LENZ Therapeutics shares in Q1 2026, an estimated $410K.
  • LENZ Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1022 holding.
  • Los Angeles Capital Management first reported a position in LENZ Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.